1. Scrip
  2. >>Business
  3. >>Deals

How The Pandemic Changed Deal-Making Between Biotechs And Big Pharma

 
• By Joseph Haas

Speakers on a panel about health care deal-making discussed the influx of capital into biotech during the past two years, how that has impacted deal-making and whether those changes will last.

Coronavirus stocks
The COVID-19 pandemic actually had a positive effect on the biotech sector, but will it last?

An unexpected but largely positive aspect of the pandemic has been the ample flow of capital into the biotechnology sector as companies came up with innovations for preventing and treating COVID-19. Investors responded out of a sense of urgency, and with that came an adjustment in the balance of power between biotechs and big pharma companies. It has reframed the landscape for biopharma business development, panelists noted at the Dechert Healthcare Deals Conference on 23 September.

Many biotechs are flush with cash, giving them greater optionality in how they advance their programs. Prices for earlier-stage and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Ipsen Boosts Cancer Pipeline With ImCheck Buy

 
• By Kevin Grogan

The Paris-based group is paying €350m upfront to get hold of Marseille-headquartered ImCheck's acute myeloid leukemia candidate.

Failing to Clinch Sale, Galapagos To Wind Down Cell Therapy Business

 
• By Manas Mishra

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.

China’s Next Wave Is First-In-Class Innovation

 
• By Jessica Merrill

Drug development in China was a discussion topic at the BioFuture conference as the country’s R&D investments begin to deliver first-in-class medicines.

Asia Deal Watch: Chugai Teams With Rani On Oral Version Of Rare Disease Antibody Drug

 
• By Joseph Haas, Jung Won Shin, Lisa Takagi, Xu Hu, and Vibha Ravi

Plus deals involving Astellas/Taysha, Haihe/Taiho, AimedBio/Boehringer Ingelheim, Takeda/Nabla, CytoMed/TC BioPharm, Specialised Therapeutics/CanariaBio, UgeneX/AviadoBio, Lupin, Kissei/Searchlight, Kazia/QIMR and Prism/Servier.

More from Business

China’s Next Wave Is First-In-Class Innovation

 
• By Jessica Merrill

Drug development in China was a discussion topic at the BioFuture conference as the country’s R&D investments begin to deliver first-in-class medicines.

Stock Watch: J&J’s $5bn Product Predictions Meet Investor Skepticism

 
• By Andy Smith

Despite announcing sales growth that is currently weathering the storm of one of its biggest losses of exclusivity and a spin-off of its orthopedic division, J&J’s stock price weakened after its earnings announcement. Investors probably wanted more visibility on MFN.

Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO

 
• By Mandy Jackson

Faeth Therapeutics raised $25m to complete a Phase II trial of its PIK3/mTOR-targeting drug combination in endometrial cancer and reported positive Phase II data at ESMO in ovarian cancer with half of the combo.